A Agilent Technologies Inc.

Agilent Announces Cutting-Edge Advances in GC/MS and LC/Q-TOF Technology at ASMS 2024

, (NYSE: A) is introducing two new products at the . The Agilent 7010D Triple Quadrupole GC/MS System which targets the food and environmental markets, offers precision and sensitivity in gas chromatography-mass spectrometry. Additionally, the Agilent ExD Cell for use with the 6545XT AdvanceBio LC/Q-TOF system, serves the biopharma market and life science research. These instruments exemplify Agilent’s unwavering commitment to advancing scientific discovery through innovative instrumentation, significantly shaping the landscape of mass spectrometry.

The (7010D GC/TQ) features the new HES 2.0 ion source, providing attogram-level sensitivity, unmatched robustness, and industry-leading uptime. Built-in intelligence, including SWARM autotune and Early Maintenance Feedback (EMF), streamlines analytical workflows and reduces unplanned instrument downtime, making it a reliable partner in navigating evolving regulatory requirements.

The 7010D GC/TQ also includes the My Green Lab Accountability, Consistency, and Transparency (ACT) Label, reflecting environmentally conscious manufacturing practices. Additionally, the MassHunter Acquisition 13.0 software enhances user experience with a refreshed interface and compliance tools, enabling users to take control of data integrity and adhere to compliance guidelines such as FDA 21 CFR Part 11, EU Annex 11, and GAMP5.

The enhances peptide and protein characterization capabilities by adding electron capture dissociation (ECD). With the trend towards increasingly complex biotherapeutics this meets the need for more thorough structural characterization.

The field installable ExD cell addon for the 6545XT is designed for researchers in the ‘discovery phase’ who are faced with diverse analytical challenges. ECD is particularly appropriate for the study of large proteins, fragile modifications, and isomeric residues – analytes which can be difficult to unambiguously characterize with traditional collision induced dissociation (CID) methods alone.

Coupled with the inherent capabilities of the 6545XT for intact protein analyses, the ExD cell is also suited for performing top to middle down characterization of large and highly charged proteins (such as antibodies) and smaller subunits (such as peptides), and the rich spectra produced can be interpreted with confidence using the ExDViewer.

“Intelligence capabilities are seamlessly integrated into instruments like the 7010D GC/TQ, recognizing the fiercely competitive landscape that is constantly evolving. Additionally, the Agilent ExD cell, in conjunction with the 6545XT AdvanceBio LC/Q-TOF, empowers scientists to meticulously scrutinize and more effectively characterize peptides—critical components in modern research and therapeutics,” stated Ken Suzuki, vice president and general manager of Agilent’s Mass Spectrometry Division.

“These cutting-edge products exemplify customer-driven innovation and excellence. By listening to our customers, we gain valuable insights into their challenges. We then channel this understanding into consistent innovation, resulting in outstanding products that precisely meet their needs,” added Suzuki.

Agilent is a leading solution provider of proven, robust, and reliable mass spectrometry technologies to a range of segments and a wide array of applications in the bio/pharma, life science research, food, and environmental markets. These new technological capabilities enable Agilent’s customers to increase data quality and interpretation while reducing the time and human attention required—more easily adapting to ever-changing market needs.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.83 billion in fiscal 2023 and employs approximately 18,000 people worldwide. Information about Agilent is available at . To receive the latest Agilent news, please subscribe to the . Follow Agilent on and .

EN
03/06/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

 PRESS RELEASE

Agilent Completes Acquisition of BIOVECTRA

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE: A) today announced the company has completed its acquisition of BIOVECTRA, a Canada-based contract development and manufacturing organization (CDMO) that specializes in biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics. This press release features multimedia. View the full release here: (Graphic: Business Wire) All closing conditions are completed, including receipt of regulatory approvals. BIOVECTRA is now part of Agilent’s Diagnostics and Genomics Group. “We are de...

 PRESS RELEASE

Agilent Announces Cash Dividend of 23.6 Cents per Share

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies, Inc. (NYSE: A) today announced a quarterly dividend of 23.6 cents per share of common stock will be paid on Oct. 23, 2024, to all shareholders of record as of the close of business on Oct. 1, 2024. The timing and amounts of future dividends are subject to determination and approval by Agilent’s board of directors. About Agilent Technologies Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life...

 PRESS RELEASE

Agilent Unveils Biopharma CDx Services Lab to Accelerate Precision Med...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- , (NYSE: A) today announced the launch of its in Carpinteria, California, following receipt of California State clinical laboratory license and Clinical Laboratory Improvement Amendments (CLIA) certificate of compliance. These credentials signify that the lab operates in accordance with CLIA regulations, which are federal standards applicable to all U.S. facilities testing human specimens for health assessment, diagnosis, prevention, or treatment of diseases. The CLIA certificate of compliance ensures high standards for accuracy and reliability in labor...

Moody's Ratings assigns Baa1 rating to Agilent's unsecured notes

Moody's Ratings (Moody's) assigned a Baa1 rating to Agilent Technologies, Inc.'s ("Agilent") new senior unsecured notes. There is no change to the company's existing Baa1 senior unsecured rating and Prime-2 commercial paper rating. The rating outlook is stable. We expect that Agilent will use proc...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch